PJ-011726 IntelliSpace Cognition MCI Study

Cognitive Function 1, Social Clinical Trial

Official title:

PJ-011726 IntelliSpace Cognition MCI Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04243642
• Other study ID #: ICBE-2-34585
• Status: Completed
• Start date: January 30, 2020
• Est. completion date: April 14, 2022

Study information

• Verified date: July 2022
• Source: Philips Electronics Nederland B.V. acting through Philips CTO organization
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to create a reference database of digital cognitive assessment data in combination with neuroimaging data of patients with mild cognitive impairment. The investigators will explore and derive correlations between parameters from routine MRI images and brain volumetric analysis and the digital cognitive data to identify parameters that are relevant to classify MCI patients vs preexisting healthy control data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 117
• Est. completion date: April 14, 2022
• Est. primary completion date: April 14, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Aged 50-80

2. Patient is able to give consent

3. MCI or amnestic MCI diagnosis by a clinical specialist, such as a neurologist - diagnosis not older than 12 months prior to inclusions date.

4. If 3D T1 MRI images are present they cannot be older than 6 months prior to the MCI clinical diagnosis was made.

5. Must be proficient in American English.

6. If patient has vision impairment or hearing loss, must be corrected to normal.

7. Must have use of fingers, hands, and arms to be able to use a pencil to write symbols.

8. Must be able to understand test instructions and participate fully in testing.

Exclusion Criteria:

1. Currently admitted to a hospital, assisted living, nursing home or a psychiatric facility.

2. Diagnosed with a (neurological) disorder other than MCI or aMCI, i.e.:

• Current primary neurodegenerative diseases (e.g., Parkinson's disease, brain tumor, dementia)
• Stroke
• Current TBI
• Current epilepsy [if # seizures = 2 and not receiving ongoing treatment for seizures, and not currently seeking medical evaluation or attention related to seizures, patient can be accepted],
• Current encephalitis
• Current language disorder (expressive or mixed receptive/expressive excluded; articulation disorder is ok)
• Current learning disorder
• Current or past psychotic disorder
• Current severe mood disorder (in the case of Major Depressive Disorder in remission or with no current episode, and Dysthymic and Adjustment disorder, examinee can be accepted)
• Current severe anxiety disorder (e.g., PTSD, GAD, OCD) with symptoms significant enough to interfere with optimal test performance (in the case of phobias, examinee can be accepted)
• Current or past Autism Spectrum Disorder or Intellectual Disability
• Primarily nonverbal or uncommunicative
• Current aphasia
• LUPUS
• Multiple Sclerosis
• Sleep apnea (moderate or severe, Apnea-Hypopnea Index <15 is acceptable)

3. Major structural intracranial abnormalities and brain disorders on prior imaging study

(in the last 12 months), i.e.:

• Major developmental disorders (e.g., polymicrogyria, schizencephaly)
• Intracranial tumors: intraaxial (brain tumors); extraaxial (tumors of bone and meninges) insofar they exert mass effect on the brain with edema or gliosis
• Chronic brain injury and acquired focal or diffuse loss of normal parenchyma regardless of the etiology (e.g. prior stroke,brain surgery, trauma, atrophy due to neurodegenerative disease such as frontotemporal degeneration; or other causes), with the exception of age related changes (e.g. mild-moderate cerebral volume loss) on either side and prior surgery that involved only the skull but not the brain
• Vascular encephalopathy, defined as Fazekas grade 2 or lower

4. Any history of having been unconscious related to TBI or "medical condition" > 20 minutes or have had any head-injury resulting in an overnight hospital stay

5. Any history of a medical event requiring resuscitation in which examinee was non-responsive for > 15 minutes

6. Currently receiving chemotherapy treatment, or have received chemotherapy treatment in the past 2 months

7. Any history of ECT or radiation to the CNS

8. Currently diagnosed with substance abuse or dependence, or have carried any substance abuse or dependence diagnosis in the past year (> 1 year in remission diagnoses are ok)

9. A current average alcohol consumption of 4 or more units per day. Long term alcohol abusers are excluded as well (e.g., abused substance for more than 10 years)

10. Currently taking medication that might impact test performance (i.e. anti- convulsants, antipsychotics, benzodiazepines, psychostimulants, opioids, tricyclic Antidepressants, Oxybutynin)

11. Disruptive behavior or insufficient compliance with testing to ensure a valid assessment

12. Non-valid health insurance in USA

Related Conditions & MeSH terms

• Cognitive Function 1, Social
• MCI

Intervention

Device:
• IntelliSpace Cognition
Philips IntelliSpace Cognition (ISC) is a digital assessment platform that supports Healthcare Professionals (HCP) in assessing the cognition of individuals. It consists of two interfaces connected to the DCDx-module in the cloud. ISC is hosted on the Philips Health Suite Digital Platform (HSDP). The first interface is the patient's interface and is presented via a tablet to collect data on how the patient performs a series of tests. The second interface is the clinician's interface and can be used on any PC or tablet. It allows for assessments to be selected and administered, observations made, data analytics performed and the generation of a report.

Locations

Country	Name	City	State
United States	DENT Neurologic Institute	Amherst	New York

Sponsors (3)

Lead Sponsor	Collaborator
Philips Electronics Nederland B.V. acting through Philips CTO organization	Dent Neurologic Institute, Qserve

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare performance of patients with Mild Cognitive Impairment	Create a database of digital cognitive assessment data in combination with neuroimaging data of patients with mild cognitive impairment to: Compare performance of patients with Mild Cognitive Impairment (MCI) to normative data of the healthy US population and characterize a MCI cognitive profile.	Feb-2020 until Dec-2021
Primary	Derive correlations between parameters	Create a database of digital cognitive assessment data in combination with neuroimaging data of patients with mild cognitive impairment to: Derive correlations between parameters derived from MRI images (NeuroQuant scores) and the digital cognitive data.	Feb-2020 until Dec-2021
Primary	Identify (combinations of) parameters	Create a database of digital cognitive assessment data in combination with neuroimaging data of patients with mild cognitive impairment to: Identify (combinations of) parameters that are relevant to classify MCI patients vs healthy controls.	Feb-2020 until Dec-2021
Primary	Explore predictive values	Create a database of digital cognitive assessment data in combination with neuroimaging data of patients with mild cognitive impairment to: Explore predictive value of combination of neuroimaging and digital cognitive outcome parameters to predict MCI to Alzheimer's disease conversion.	Feb-2020 until Dec-2021
Secondary	Exploratory analysis to find new outcome measures from the raw input data of the digital cognitive tests.		Feb-2020 until Dec-2021
Secondary	Evaluate the performance of ISC scoring algorithms.		Feb-2020 until Dec-2021
Secondary	To explore usability aspects of ISC with MCI patients.		Feb-2020 until Dec-2021